Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Priya Maseelall

Reproductive Endocrinology Akron, OH Medical Doctor

NPI 1699945790 CMS profile 303421

95 Arch St, Suite 250, Akron, OH 44304

Open in the dashboard

General payments

$4,730

187 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Priya Maseelall of Akron, OH is reported in the CMS Open Payments database as having received $4,730 across 187 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $542 12
2024 General $350 16
2023 General $382 12
2022 General $276 13
2021 General $337 18
2020 General $1,424 33
2019 General $1,419 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Priya Maseelall
  • Reproductive Endocrinology median
  • Middle half of Reproductive Endocrinology
  • National median

In program year 2025, general payments to Priya Maseelall were reported at $542. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.

Show as a table
Year Priya Maseelall Reproductive Endocrinology median Middle half National median
2019 $1,419 $196 $77–$425 $163
2020 $1,424 $81 $35–$182 $114
2021 $337 $102 $43–$247 $132
2022 $276 $139 $62–$303 $149
2023 $382 $141 $65–$285 $160
2024 $350 $144 $65–$302 $164
2025 $542 $141 $66–$285 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ferring Pharmaceuticals Inc. $1,791 38 payments
  2. Organon LLC $999 43 payments
  3. Merck Sharp & Dohme Corporation $532 29 payments
  4. AbbVie, Inc. $504 13 payments
  5. Avion Pharmaceuticals $288 27 payments
  6. CooperSurgical, Inc. $242 10 payments
  7. Vertical Pharmaceuticals, LLC $123 8 payments
  8. EMD Serono, Inc. $108 10 payments
  9. Hologic, LLC $44 2 payments
  10. Duchesnay USA Incorporated $26 2 payments
  11. Other $72 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,773 176 payments
  2. Travel and Lodging $939 9 payments
  3. Education $18 2 payments
Products named General payments · program years 2019–2025
  1. INVOCELL $1,158 17 payments
  2. PREGNYL $743 31 payments
  3. GANIRELIX ACETATE $670 26 payments
  4. FOLLISTIM AQ Follitropin $655 27 payments
  5. FOLLISTIM AQ Womens Health $532 29 payments
  6. MENOPUR $351 18 payments
  7. Orilissa $345 9 payments
  8. GANIRELIX $298 17 payments
  9. Balcoltra $277 26 payments
  10. STRIPPER $147 4 payments
  11. Other $873 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

187 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Reproductive Endocrinology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record